AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
Log in

NASDAQ:EGLTEgalet Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.33
0.00 (0.00 %)
(As of 05/29/2020 01:52 PM ET)
Add
Compare
Today's Range
$0.33
Now: $0.33
$0.33
50-Day Range
$0.01
MA: $0.24
$0.33
52-Week Range
$0.03
Now: $0.33
$1.57
VolumeN/A
Average Volume853,425 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
Read More
Egalet logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGLT
CUSIPN/A
Phone610-833-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive EGLT News and Ratings via Email

Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter.

Egalet (NASDAQ:EGLT) Frequently Asked Questions

How were Egalet's earnings last quarter?

Egalet (NASDAQ:EGLT) posted its earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.06. The specialty pharmaceutical company earned $7.44 million during the quarter, compared to the consensus estimate of $8.64 million. View Egalet's earnings history.

Has Egalet been receiving favorable news coverage?

Media coverage about EGLT stock has trended positive on Friday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Egalet earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the near future. View the latest news aboutEgalet.

Who are some of Egalet's key competitors?

What other stocks do shareholders of Egalet own?

Who are Egalet's key executives?

Egalet's management team includes the following people:
  • Mr. Robert S. Radie, Pres, CEO & Director (Age 55)
  • Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)
  • Dr. Mark Strobeck, Exec. VP & COO (Age 47)
  • Ms. Barbara A. Carlin, Sr. VP & Chief Accounting Officer (Age 43)
  • Dr. Karsten Lindhardt M.Sc., Ph.D., Chief Scientific Officer (Age 46)

What is Egalet's stock symbol?

Egalet trades on the NASDAQ under the ticker symbol "EGLT."

What is Egalet's stock price today?

One share of EGLT stock can currently be purchased for approximately $0.33.

What is Egalet's official website?

The official website for Egalet is www.egalet.com.

How can I contact Egalet?

Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.